Liraglutide
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Novo Nordisk · Phase 3 · Completed · Enrollment 3731
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | n/r | n/r | n/r | n/r |
| Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68) | n/r | n/r | n/r | n/r |
| Liraglutide Placebo, no Pre-diabetes | n/r | n/r | n/r | n/r |
| Liraglutide 3.0mg, Pre-diabetes | n/r | n/r | n/r | n/r |
| Liraglutide Placebo, Pre-diabetes | 23.7% | 10.6% | n/r | n/r |
| Liraglutide 3.0 mg (56-Week) | 49.6% | 33.1% | n/r | n/r |
Not shown
- Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68): endpoint not reported
- Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68): endpoint not reported
- Liraglutide Placebo, no Pre-diabetes: endpoint not reported
- Liraglutide 3.0mg, Pre-diabetes: endpoint not reported